NCT02139267View on ClinicalTrials.gov

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Cervical Intraepithelial Neoplasia
Interventions
BIOLOGICAL

GX-188E

DNA vaccine administered via IM route using TDS-IM electroporation device

Trial Locations (4)

700-712

Keimyung University Dongsan Medical Center, Daegu

100-380

Cheil General Hospital & Women's Healthcare Center, Seoul

137-701

The Catholic University of Korea Seoul St.Mary's Hospital, Seoul

152-703

Korea University Guro Hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT02139267 - Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia | Biotech Hunter | Biotech Hunter